Literature DB >> 31646273

The impact of glucose-lowering medications on cardiovascular disease.

Angelo Avogaro1, Saula Vigili De Kreutzenberg1, Gian Paolo Fadini1.   

Abstract

Patients with type 2 diabetes mellitus die most frequently from cardiovascular disease. Metabolic control is mandatory both for preventing long-term complications and for reducing the negative effects of the exposure of the other risk factors. In this article, we will describe the most commonly used glucose-lowering agents, the pathophysiological mechanisms underlying their cardiovascular protection, the available evidence-based data for this protection, and the contraindications and potential adverse effects.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular outcome trials; diabetes type 2; glucagon-like peptide 1 receptor agonists; macrovascular complications; microvascular complications; sodium–glucose cotransporters 2

Year:  2018        PMID： 31646273      PMCID： PMC6739886          DOI： 10.1097/XCE.0000000000000139

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol Metab        ISSN： 2574-0954


  71 in total

1.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.

Authors:  Lawrence H Young; Catherine M Viscoli; Jeptha P Curtis; Silvio E Inzucchi; Gregory G Schwartz; Anne M Lovejoy; Karen L Furie; Mark J Gorman; Robin Conwit; J Dawn Abbott; Daniel L Jacoby; Daniel M Kolansky; Steven E Pfau; Frederick S Ling; Walter N Kernan
Journal:  Circulation       Date:  2017-02-28       Impact factor: 29.690

Review 3.  Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.

Authors:  Huilin Tang; Zhenwei Fang; Tiansheng Wang; Wei Cui; Suodi Zhai; Yiqing Song
Journal:  Am J Cardiol       Date:  2016-08-31       Impact factor: 2.778

4.  Metformin and risk of long-term mortality following an admission for acute heart failure.

Authors:  Lorenzo Fácila; Óscar Fabregat-Andrés; Vicente Bertomeu; Juan P Navarro; Gema Miñana; Sergio García-Blas; Ernesto Valero; Salvador Morell; Juan Sanchis; Julio Núñez
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2017-02       Impact factor: 2.160

5.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

6.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

7.  Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.

Authors:  David Preiss; Suzanne M Lloyd; Ian Ford; John J McMurray; Rury R Holman; Paul Welsh; Miles Fisher; Chris J Packard; Naveed Sattar
Journal:  Lancet Diabetes Endocrinol       Date:  2013-11-07       Impact factor: 32.069

8.  Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.

Authors:  Christianne L Roumie; Jea Young Min; Lucy D'Agostino McGowan; Caroline Presley; Carlos G Grijalva; Amber J Hackstadt; Adriana M Hung; Robert A Greevy; Tom Elasy; Marie R Griffin
Journal:  J Am Heart Assoc       Date:  2017-04-19       Impact factor: 5.501

9.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Authors:  Mikhail Kosiborod; Matthew A Cavender; Alex Z Fu; John P Wilding; Kamlesh Khunti; Reinhard W Holl; Anna Norhammar; Kåre I Birkeland; Marit Eika Jørgensen; Marcus Thuresson; Niki Arya; Johan Bodegård; Niklas Hammar; Peter Fenici
Journal:  Circulation       Date:  2017-05-18       Impact factor: 29.690

10.  Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms.

Authors:  Jerzy Bełtowski; Jolanta Rachańczyk; Mirosław Włodarczyk
Journal:  PPAR Res       Date:  2013-03-18       Impact factor: 4.964
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.